Insider
AbbVie Inc.ABBV

AbbVie reports revenue growth and raises annual guidance

AbbVie reported $17.404 billion in net revenue for the third quarter of 2026, a 10.3% increase year-over-year. Diluted earnings per share (EPS) was $2.37 on a GAAP basis, and $3.82 on an adjusted basis. The company raised its full-year adjusted EPS guidance to $13.95–$13.99.

Verified against 1 archived primary source · SHA-256 recorded Inspect sources & citations ↓
white and red exit sign
Photo by Cory Mogk on Unsplash
$17.404 billion
Third-quarter net revenue
$683 million
Humira revenue
10.3%
Revenue growth, y/y

Key points

  • The 10.3% revenue growth occurred as Humira revenue declined 31.2% to $683 million.
  • The annual profit guidance includes a $0.69 per share negative impact from acquired in-process research and development (IPR&D) and milestone expenses.

Financial results and dividends

The 10.3% revenue growth occurred as Humira revenue declined 31.2% to $683 million. The board of directors declared a quarterly dividend increase from $1.73 to $1.82 per share. The new payout takes effect February 16, 2027, for shareholders of record as of January 15, 2027.

During the quarter, the company completed the acquisition of Apogee Therapeutics to develop its immunology pipeline. AbbVie also entered agreements with Valkai and Iambic to integrate artificial intelligence into drug development and accelerate the discovery of new molecules in immunology, neuroscience, and oncology.

Third-quarter financial results

Net revenue
$17.4 billion
Humira revenue
$683 million
Data from the original sources listed alongside.

Revenue by quarter, $B

15.1Q4 '24-9.9%13.3Q1 '2528%15.4Q2 '2531.7%15.8Q3 '2512.1%16.6Q4 '2527.3%15Q1 '2626.6%17Q2 '2637.9%17.4Q3 '2636%
Bottom row: operating margin (operating income divided by revenue). Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Risks and outlook

The annual profit guidance includes a $0.69 per share negative impact from acquired in-process research and development (IPR&D) and milestone expenses. Integration costs for the Apogee Therapeutics acquisition are reflected in special reporting items that may affect operating performance.

Key takeaways

Shareholders should track dividend payments in February 2027. Another key metric remains meeting the updated full-year adjusted EPS guidance of $13.95–$13.99, which will be reflected in future financial reports.

Original sources

  1. 8-K EX-99.1 filing, October 30, 2026October 30, 2026SHA-256 of our archived copy 4468a396f955…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards